Faster clinical recovery with ensovibep compared to placebo in patients with mild-to-moderate COVID-19: interim results from the EMPATHY Phase 2 trial
R. Chandra (East Hanover, United States), L. Abrishamian (Torrance, United States), M. Bonten (Utrecht, Netherlands), P. Fustier (Zurich-Schlieren, Switzerland), K. Gedif (Fort Worth, Tx, United States), S. Goncalves (Basel, Switzerland), A. Igbinadolor (Monroe, United States), J. Kingsley (Columbus, United States), C. Knutson (Cambridge, United States), N. Kumarasamy (Chennai, India), P. Legenne (Zurich-Schlieren, Switzerland), M. Mekebeb-Reuter (George, South Africa), K. Ramanathan (Basel, Switzerland), E. Reshetnyak (East Hanover, United States), J. Rosa (Gauteng, South Africa), M. Soergel (Zurich-Schlieren, Switzerland), D. Solai Elango (Hyderabad, India), V. Stavropoulou (Zurich-Schlieren, Switzerland), N. Stojcheva (Zurich-Schlieren, Switzerland), M. Stumpp (Zurich-Schlieren, Switzerland), A. Tietz (Basel, Switzerland)
Source: International Congress 2022 – What's new in COVID
Session: What's new in COVID
Session type: Oral Presentation
Number: 3796
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Chandra (East Hanover, United States), L. Abrishamian (Torrance, United States), M. Bonten (Utrecht, Netherlands), P. Fustier (Zurich-Schlieren, Switzerland), K. Gedif (Fort Worth, Tx, United States), S. Goncalves (Basel, Switzerland), A. Igbinadolor (Monroe, United States), J. Kingsley (Columbus, United States), C. Knutson (Cambridge, United States), N. Kumarasamy (Chennai, India), P. Legenne (Zurich-Schlieren, Switzerland), M. Mekebeb-Reuter (George, South Africa), K. Ramanathan (Basel, Switzerland), E. Reshetnyak (East Hanover, United States), J. Rosa (Gauteng, South Africa), M. Soergel (Zurich-Schlieren, Switzerland), D. Solai Elango (Hyderabad, India), V. Stavropoulou (Zurich-Schlieren, Switzerland), N. Stojcheva (Zurich-Schlieren, Switzerland), M. Stumpp (Zurich-Schlieren, Switzerland), A. Tietz (Basel, Switzerland). Faster clinical recovery with ensovibep compared to placebo in patients with mild-to-moderate COVID-19: interim results from the EMPATHY Phase 2 trial. 3796
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|